These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 7962520

  • 1. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
    Basta M, Dalakas MC.
    J Clin Invest; 1994 Nov; 94(5):1729-35. PubMed ID: 7962520
    [Abstract] [Full Text] [Related]

  • 2. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies.
    Dalakas MC.
    Clin Exp Immunol; 1996 May; 104 Suppl 1():55-60. PubMed ID: 8625545
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
    Barbasso Helmers S, Dastmalchi M, Alexanderson H, Nennesmo I, Esbjörnsson M, Lindvall B, Lundberg IE.
    Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
    [Abstract] [Full Text] [Related]

  • 5. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis.
    Dalakas MC.
    Int Immunopharmacol; 2006 Apr; 6(4):550-6. PubMed ID: 16504918
    [Abstract] [Full Text] [Related]

  • 6. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
    Raju R, Dalakas MC.
    Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
    [Abstract] [Full Text] [Related]

  • 7. [Immunoglobulin deposition in skeletal muscle in polymyositis and dermatomyositis].
    Chen L, Guo Y.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Feb; 15(1):55-7. PubMed ID: 8324838
    [Abstract] [Full Text] [Related]

  • 8. In vitro comparison of the complement-scavenging capacity of different intravenous immunoglobulin preparations.
    Spycher M, Matozan K, Minnig K, Zehnder R, Miescher S, Hoefferer L, Rieben R.
    Vox Sang; 2009 Nov; 97(4):348-54. PubMed ID: 19656348
    [Abstract] [Full Text] [Related]

  • 9. Complement C3 deposition onto bacteria by neonatal serum is not enhanced after the infusion of intravenous immunoglobulin.
    Lassiter HA, Speranza MJ, Hall RT, Meade V, Christensen RD, Parker CJ.
    J Perinatol; 1990 Mar; 10(1):27-31. PubMed ID: 2107285
    [Abstract] [Full Text] [Related]

  • 10. Microvascular deposition of complement membrane attack complex in dermatomyositis.
    Kissel JT, Mendell JR, Rammohan KW.
    N Engl J Med; 1986 Feb 06; 314(6):329-34. PubMed ID: 3945256
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. C5b-9 deposits on endomysial capillaries in non-dermatomyositis cases.
    Braczynski AK, Harter PN, Zeiner PS, Drott U, Tews DS, Preusse C, Penski C, Dunst M, Weis J, Stenzel W, Mittelbronn M.
    Neuromuscul Disord; 2016 Feb 06; 26(4-5):283-91. PubMed ID: 27020463
    [Abstract] [Full Text] [Related]

  • 13. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.
    Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S.
    N Engl J Med; 1993 Dec 30; 329(27):1993-2000. PubMed ID: 8247075
    [Abstract] [Full Text] [Related]

  • 14. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials.
    Dalakas MC.
    Neurol Sci; 2003 Oct 30; 24 Suppl 4():S256-9. PubMed ID: 14598055
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravenous immunoglobulin prevents experimental autoimmune myositis in SJL mice by reducing anti-myosin antibody and by blocking complement deposition.
    Wada J, Shintani N, Kikutani K, Nakae T, Yamauchi T, Takechi K.
    Clin Exp Immunol; 2001 May 30; 124(2):282-9. PubMed ID: 11422206
    [Abstract] [Full Text] [Related]

  • 17. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW, Kadlec JV, Petrella EC, Bredehorst R, Vogel CW.
    Cancer Res; 1993 Feb 01; 53(3):592-9. PubMed ID: 8425193
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
    Dalakas MC.
    Pharmacol Ther; 2004 Jun 01; 102(3):177-93. PubMed ID: 15246245
    [Abstract] [Full Text] [Related]

  • 20. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
    Breems DA, de Haas PW, Visscher F, Sabbe LJ, Busch HF, van Doorn PA.
    Ned Tijdschr Geneeskd; 1993 Sep 25; 137(39):1979-82. PubMed ID: 8413708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.